Julia Dou

R&D Director

Degron Therapeutics

Short Biography

Dr. Julia Dou currently serves as the Director at Degron Therapeutics, with a strong academic background and extensive industry experience in structural biology and biochemistry. She specializes in ubiquitin signaling, protein interactions, and drug screening, and is proficient in techniques such as crystallography, cryo-EM, and proteomics.  She has successfully developed multiple innovative technology platforms and has made significant contributions to the structural analysis of molecular glue complexes and the discovery of new molecular glue targets. Dr. Dou obtained her Ph.D. from the University of Glasgow and previously held the position of Associate Professor at Shandong University. She also participated in research collaborations as a visiting scientist at the University of Oxford.

Presentation Topic: First-in-class molecular glue degraders targeting undruggable targets

• Targeted protein degradation offers novel therapeutic strategies for diseases

• Molecular glues degraders redirect E3 ligases to mark new targets for destruction

• Works on proteins lacking traditional druggable sites, expanding the "undruggable"

• Key breakthroughs, current hurdles, and the future landscape of molecular glue degraders